Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1085246 | 1.00 | BRS3 (0.58) | BRS3NR1I2 | |
| SCHEMBL1085498 | 0.90 | BRS3 (0.64) | BRS3NR1I2 | |
| SCHEMBL1085499 | 0.90 | BRS3 (0.64) | BRS3NR1I2 | |
| SCHEMBL1085446 | 0.88 | BRS3 (0.74) | BRS3NR1I2 | |
| SCHEMBL1085445 | 0.88 | BRS3 (0.74) | BRS3NR1I2 | |
| SCHEMBL1085833 | 0.87 | BRS3 (0.74) | BRS3NR1I2 | |
| SCHEMBL1085832 | 0.87 | BRS3 (0.74) | BRS3NR1I2 | |
| SCHEMBL1085248 | 0.85 | BRS3 (0.56) | BRS3NR1I2 | |
| SCHEMBL1085698 | 0.80 | BRS3 (0.58) | BRS3NR1I2 | |
| SCHEMBL1090473 | 0.80 | BRS3 (0.74) | BRS3NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153626-B2 | Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100317645-A1 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS | MERCK SHARP & DOHME LLC | 2010-12-16 | — | — | US | disclosed |
| EP-2102201-B1 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK SHARP & DOHME (US) | 2010-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317645-A1 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS | BRS3, BRSK1, BRSK2 | BRS3 1/4885NR1I2 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.